Seminars in thrombosis and hemostasis最新文献_第5页

International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls. 国际血液学标准化委员会凝固试剂、校准器和对照品新批号验证指南。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-11-15 DOI: 10.1055/s-0043-1776405

Robert C Gosselin, Donna Castellone, Akbar Dorgalaleh, Kieron Hickey, Giuseppe Lippi, Karen Moffat, Rebecca O'Toole, Joe Rigano

引用次数: 0

Erratum: Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden. 勘误表：活性蛋白C抗性和因子V莱顿的实验室诊断。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-10-25 DOI: 10.1055/s-0043-1776324

Mehran Bahraini, Alieh Fazeli, Akbar Dorgalaleh

引用次数: 0

Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice. 肝素的多生物效应及其在临床实践中的监控。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-05-29 DOI: 10.1055/s-0044-1786990

Deepa J Arachchillage, Steve Kitchen

{"title":"Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice.","authors":"Deepa J Arachchillage, Steve Kitchen","doi":"10.1055/s-0044-1786990","DOIUrl":"10.1055/s-0044-1786990","url":null,"abstract":"Unfractionated heparin (UFH) was uncovered in 1916, has been used as an anticoagulant since 1935, and has been listed in the World Health Organization's Model List of Essential Medicines. Despite the availability of many other anticoagulants, the use of heparin (either low molecular weight heparin [LMWH] or UFH) is still substantial. Heparin has pleotropic effects including anticoagulant and several nonanticoagulant properties such as antiproliferative, anti-inflammatory activity, and anticomplement effects. Although UFH has been widely replaced by LMWH, UFH is still the preferred anticoagulant of choice for patients undergoing cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, and patients with high-risk mechanical cardiac valves requiring temporary bridging with a parenteral anticoagulant. UFH is a highly negatively charged molecule and binds many positively charged molecules, hence has unpredictable pharmacokinetics, and variable anticoagulant effect on an individual patient basis. Therefore, anticoagulant effects of UFH may not be proportional to the dose of UFH given to any individual patient. In this review, we discuss the anticoagulant and nonanticoagulant activities of UFH, differences between UFH and LMWH, when to use UFH, different methods of monitoring the anticoagulant effects of UFH (including activated partial thromboplastin time, heparin anti-Xa activity level, and activated clotting time), while discussing pros and cons related to each method and comparison of clinical outcomes in patients treated with UFH monitored with different methods based on available evidence.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1153-1162"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2023 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. 2023 年埃伯哈德-马门奖公告：第二部分 - 青年研究员奖。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-01 DOI: 10.1055/s-0044-1787989

Emmanuel J Favaloro

引用次数: 0

New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. 新 STH 2023 影响因子、高被引论文及其他期刊指标。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788566

Emmanuel J Favaloro

引用次数: 0

Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part III. 血栓与止血检测的实验室诊断--第 3 部分。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788567

Kristi J Smock, Karen A Moffat

引用次数: 0

Platelet Pathophysiology: Unexpected New Research Directions. 血小板病理生理学：意想不到的新研究方向

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-06-18 DOI: 10.1055/s-0044-1787663

Alan D Michelson, Andrew L Frelinger Iii, Robin L Haynes, Hannah C Kinney, Thomas Gremmel

引用次数: 0

Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden. 活性蛋白C抗性和因子V莱顿的实验室诊断。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-07-10 DOI: 10.1055/s-0043-1770773

Mehran Bahraini, Alieh Fazeli, Akbar Dorgalaleh

引用次数: 0

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond. 血栓性血小板减少性紫癜及其他疾病的 ADAMTS13 实验室检测。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-28 DOI: 10.1055/s-0044-1792003

Emmanuel J Favaloro, Leonardo Pasalic, Giuseppe Lippi

{"title":"Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond.","authors":"Emmanuel J Favaloro, Leonardo Pasalic, Giuseppe Lippi","doi":"10.1055/s-0044-1792003","DOIUrl":"https://doi.org/10.1055/s-0044-1792003","url":null,"abstract":"ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also called von Willebrand factor (VWF) cleaving protease, acts as a moderator of VWF activity. ADAMTS13 cleaves VWF multimers, thereby reducing VWF activity in blood. When ADAMTS13 is absent (e.g., in patients with TTP [thrombotic thrombocytopenia purpura]), accumulation of VWF in plasma can occur, particularly as \"ultra-large\" VWF multimers, with this leading to adverse outcomes such as thrombosis. Relative ADAMTS13 deficiencies also occur in several other conditions, including secondary thrombotic microangiopathies (TMA), cancer, and with severe infections such as in COVID-19 (coronavirus disease 2019). These situations might therefore be accompanied with relative loss of ADAMTS13, thereby potentially also leading to pathological VWF accumulation, with this then generating a prothrombotic milieu, thus contributing to enhance the risk of thrombosis. Laboratory testing for ADAMTS13 can aid in the diagnosis of such disorders (i.e., TTP, TMA), and help guide their management, with testing now accomplished using various assays. As most presentations of TTP reflect an acquired condition due to anti-ADAMTS13 antibodies, there may also be a need to test for these, as this will also influence clinical management. We herein provide an overview of TTP, note other conditions in which low levels of ADAMTS13 may be present, and then detail laboratory testing for both ADAMTS13 and associated inhibitors.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

D-dimer-An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World. D-二聚体--实验室检测质量的国际评估：在现实世界中使用二聚体的意义》。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-17 DOI: 10.1055/s-0044-1791700

Carolyne Elbaz, Martine J Hollestelle, Piet Meijer, Zachary Liederman, Rita Selby

{"title":"D-dimer-An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World.","authors":"Carolyne Elbaz, Martine J Hollestelle, Piet Meijer, Zachary Liederman, Rita Selby","doi":"10.1055/s-0044-1791700","DOIUrl":"https://doi.org/10.1055/s-0044-1791700","url":null,"abstract":"D-dimer assessment has several established roles in venous thromboembolism (VTE) and disseminated intravascular coagulation diagnosis, and recently the risk stratification of coronavirus disease 2019 (COVID-19). D-dimer assays are neither standardized nor harmonized, use varying methodologies, and use different reporting units, all resulting in a lack of interchangeability and generalizability of assays. Using large multiyear datasets from an international laboratory quality assurance program, we assessed (1) common D-dimer assays in use worldwide, (2) differences in analytical performance between different methods, and (3) interlaboratory variability between positive samples. External proficiency testing results from laboratories participating in the External Quality Control for Assays and Tests (ECAT) Foundation were analyzed from 2017 to 2023. Annually, between 578 and 690 laboratories participated in the D-dimer sample surveys with response rates ranging from 88 to 97%. The three most common assays in use in 2023 were the Siemens Innovance D-dimer (42%), the IL HemosIL D-dimer HS 500 (20%), and the Diagnostica Stago (Stago) Liatest D-dimer Plus (10%)-all these are automated, quantitative, latex immunoassays expressed in fibrinogen equivalent units (FEU). The highest interlaboratory variability was observed around the typical VTE exclusion threshold of 0.5 mg/L FEU. Lower interlaboratory variability was observed at values above 0.8 mg/L FEU. Our study provides recent, international performance data on currently used D-dimer assays and describes the significant variability between assays and across D-dimer concentrations. We demonstrate that assays are not interchangeable and that using them interchangeably has the potential to result in clinically important errors. There is an urgent need to educate users about these issues and to work towards harmonizing D-dimer units and reporting.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0